Registry for patients treated with metreleptin for lipodystrophy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, observational registry that collects data on patients receiving metreleptin treatment for generalized and partial lipodystrophy. The study aims to gather real-world evidence on the safety and effectiveness of metreleptin, focusing on various adverse events and treatment outcomes. Patients enrolled in the registry will be monitored for complications such as pancreatitis, hepatic events, and autoimmune disorders, contributing to a better understanding of metreleptin's impact in routine clinical practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients treated with metreleptin through commercial supply at the time or before enrolment into registry
* Patients who provide a written consent
* Patient coming off metreleptin clinical studies and continuing or restarting treatment with metreleptin through commercial supply

Exclusion Criteria:

• Patients currently treated with an investigational agent as part of a clinical trial

Where it's running

• Ann & Robert H. Lurie Children's Hospital of Chicago
  Chicago, Illinois, United States Recruiting
• University of Kansas Medical Center Research Institute, Inc.
  Kansas City, Kansas, United States Recruiting
• Nih/Niddk/Deob
  Bethesda, Maryland, United States Recruiting
• University of Michigan
  Ann Arbor, Michigan, United States Recruiting
• Childrens Hospital of Michigan
  Detroit, Michigan, United States Recruiting
• Endocrinology Research Associates
  Columbus, Ohio, United States Recruiting

Study contacts

• Study coordinator: Lori Hartnett
• Email: clinicaltrials_info@chiesi.com
• Phone: +3905212791

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating Metreleptin for Partial Lipodystrophy

  This study is testing if daily injections of Metreleptin can help people with partial lipodystrophy manage their symptoms better.

  Recruiting at 9 sites Phase 4 Amryt Pharma · Lille and 11 other locations · NCT06484868

• Blocking growth hormone to help with severe insulin resistance

  This study is testing if a medication that blocks growth hormone can help people with severe insulin resistance feel better and improve their metabolism.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05470504

• Identifying insulin-resistant PCOS with LMNA-related lipodystrophy in young women

  We’re testing whether women with a genetic insulin resistance and lipodystrophy differ from women with PCOS by age and BMI matching.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07412028

• Long-term evaluation of Metreleptin for patients with partial lipodystrophy

  This study is testing if long-term daily use of Metreleptin can help people with familial partial lipodystrophy feel better and improve their health.

  Recruiting at 7 sites Phase 3 Chiesi Farmaceutici S.p.A. · Birmingham, Alabama and 6 other locations · NCT06679270

• Tirzepatide to improve blood sugar and triglycerides in partial lipodystrophy

  This trial will see if tirzepatide can help adults with familial partial lipodystrophy lower blood sugar and triglycerides by reducing how much they eat.

  Recruiting Phase 2 University of Michigan · Ann Arbor, Michigan · NCT07091734

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.